VASO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• ●Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp.…

• Gross profit for the three months ended March 31, 2026 and 2025 was $11,576,000, or 60% of revenue, and $11,358,000, or 58% of revenue, respectively, representing an increase of $218,000, or 2%, year-over-year. On a segment basis, gross profit in the professional sales service segment increased $328…

• IT segment gross profit for the three months ended March 31, 2026 was $4,055,000, or 42% of the segment revenue, compared to $4,138,000, or 40% of the segment revenue, for the three months ended March 31, 2025. The year-over-year decrease of $83,000, or 2%, was due to $416,000 lower gross profit res…

• Professional sales service segment gross profit was $7,222,000, or 78% of segment revenue, for the three months ended March 31, 2026 as compared to $6,894,000, or 79% of segment revenue, for the three months ended March 31, 2025, reflecting an increase of $328,000, or 5%. The increase was primarily …

• Commission expense associated with short-term deferred revenue is recorded as Deferred commission expense, or with long-term deferred revenue as part of Other assets, net, on the condensed consolidated balance sheets until the related commission revenue is recognized.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• ●Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively, primarily focuses on the design, manufacture, sale and service of…

• On September 17, 2024 Vaso provided notice to Achari to terminate its previously disclosed Business Combination Agreement with Achari. Vaso intends to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships and strategic investments with a co…

• IT segment gross profit for the three months ended September 30, 2025 was $4,733,000, or 42% of the segment revenue, compared to $4,111,000, or 37% of the segment revenue for the three months ended September 30, 2024. The year-over-year increase of $622,000, or 15%, was primarily a result of a highe…

• Professional sales service segment gross profit was $8,747,000, or 81% of segment revenue, for the three months ended September 30, 2025 as compared to $7,276,000, or 80% of the segment revenue, for the three months ended September 30, 2024, reflecting an increase of $1,471,000, or 20%. The increase…

• Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• 3(ii) Amended and Re-stated Bylaws (Incorporated by reference to Report on Form 8-K filed February 12, 2026).

• 4 Specimen Certificate for Common Stock (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).

• 31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

• 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• 3(ii) Bylaws (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).

• 31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

• 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.